. Author manuscript; available in PMC: 2014 May 23.

Published in final edited form as: Clin Pharmacol Ther. 2012 Dec 24;93(4):326–334. doi: 10.1038/clpt.2012.249

Table 4.

Secondary outcomes

Characteristic	Placebo (n = 38)	EACA (n = 37)	HOE 140 (n = 40)	P value	EACA vs. placebo OR (95% CI)	HOE 140 vs. placebo OR (95% CI)
Re-exploration for bleeding, n (%)	1 (2.6)	1 (2.7)	1 (2.5)	1.0^a	1.01 (0.25–4.13)	0.97 (0.24–3.97)
Prolonged ventilation (>24 h), n (%)	4 (10.5)	1 (2.7)	3 (7.5)	0.48^a	0.61 (0.37–1.001)	0.84 (0.42–1.66)
New postoperative AF, n (%)	5 (13.2)	5 (13.5)	9 (22.5)	0.45^a	1.02 (0.52–1.97)	1.44 (0.69–3.03)
Permanent pacemaker placement, n (%)	2 (5.3)	2 (5.4)	3 (7.5)	1.0^a	1.01 (0.37–2.77)	1.23 (0.41–3.70)
Acute kidney injury^b, n (%)	7 (18.4)	4 (10.8)	6 (15.0)	0.65^a	0.76 (0.46–1.27)	0.89 (0.50–1.56)
Readmitted within 30 days, n (%)	7 (18.9)	2 (5.9)	3 (7.7)	0.20^a	0.62 (0.40–0.96)	0.65 (0.40–1.05)
Length of hospital stay (days)	7.5 ± 1.1	5.8 ± 0.3	6.6 ± 0.6	0.84^c

HOE 140 is a specific bradykinin B₂ receptor antagonist.

AF, atrial fibrillation; CI, confidence interval; EACA, ε-aminocaproic acid; OR, odds ratio.

χ² test;

Acute kidney injury was defined according to Acute Kidney Injury Network criteria as an increase in subject serum creatinine concentration of 50% or 0.3 mg/dl within 48 h of surgery;

Kruskal–Wallis test.